The cytokine IL-17 is now a target for an array of therapeutic monoclonal antibodies
supposed to treat a variety of inflammatory diseases. The forerunner Secukinumab, an IL-
17A neutralizing antibody, is meanwhile approved as first-line treatments for moderate-to-
severe plaque psoriasis, and as second-line treatment for psoriatic arthritis and ankylosing
spondylitis. Ixekizumab and Brodalumab, both also targeting the IL-17 pathway, were also
recently approved by the FDA for plaque psoriasis. Using mice overexpressing IL-17A in a …